In a collaborative project led by the University of Oxford, diagnostic artificial intelligence (AI) applications from Paige are being trialled as part of a live, multisite clinical use study to evaluate AI in the diagnosis of prostate cancer within the NHS.
Participating in the study are North Bristol NHS Trust Southmead Hospital, University Hospitals Coventry and Warwickshire NHS Trust and Oxford University NHS Foundation Trust.
Each hospital uses different digital pathology scanners and information systems and serves distinct patient populations - but are all adding Paige’s AI technology to their standard of care to determine the potential to improve patient outcomes against a background of rising instances of prostate cancer.
The Paige Prostate Suite is a system of diagnostic AI applications designed to help pathologists detect, grade and measure tumours in prostate biopsies and tissue samples. Pathologists at these three hospitals are assessing how Paige Prostate Suite impacts their clinical decision-making, pathology service delivery, and use of resources in a real-world setting. With this use across multiple hospitals, pathologists can assess the ways Paige’s AI technology can best serve patients, histopathologists, and hospital systems for prostate cancer diagnosis.
This development is the latest achievement of the ARTICULATE PRO study, funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, overseen by the Department of Health and Social Care.
“The central focus of ARTICULATE PRO is patients. We are striving towards our goal to safely and effectively ensure they benefit the most from powerful AI technology,” said Professor Clare Verrill, OUH Cellular Pathology Consultant, Associate Professor and Principal Investigator of ARTICULATE PRO. “With the multisite live use of The Paige Prostate Suite, we can systematically study benefits to patients in clinical settings.”
Dr Jon Oxley, uropathologist and Bristol lead of ARTICULATE PRO, added: “I have studied the disease and progression of prostate cancer in clinical research for over 25 years, it is a significant advancement that Paige’s AI applications have achieved a level of validation and performance that allows safe and effective live clinical use. Using Paige Prostate Suite alongside our standard of care has the promise to increase efficiency and improve reproducibility of results for patients.”